Skip to main content

REVIEW article

Front. Allergy
Sec. Mechanisms in Allergy
Volume 5 - 2024 | doi: 10.3389/falgy.2024.1462985
This article is part of the Research Topic Aspirin-exacerbated Respiratory Disease: Molecular Mechanism, Management and Treatment View all 4 articles

NONSTEROIDAL ANTIINFLAMMATORY DRUG-EXACERBATED RESPIRATORY DISEASE: MOLECULAR MECHANISM, MANAGEMENT AND TREATMENT

Provisionally accepted
Jose De Jesus Ley Tomas Jose De Jesus Ley Tomas Ana Michelle Xicotencatl Tellez Ana Michelle Xicotencatl Tellez María De La Luz Hortensia Garcia Cruz María De La Luz Hortensia Garcia Cruz Marcos Alejandro Jimenez Chobillon Marcos Alejandro Jimenez Chobillon *
  • IAPA 's clinic, Department of Otorhinolaryngology–Head and Neck Surgery, National Institute of Respiratory Diseases-Mexico (INER), Mexico City, México, Mexico

The final, formatted version of the article will be published soon.

    It has been estimated that Nonsteroidal Anti-inflammatory drug (NSAIS) Exacerbated Respiratory Disease (N-ERD) previously named as Aspirin Exacerbated Respiratory Disease (A-ERD) affects around 1.4 million persons in the United States. Its prevalence in asthmatic patients has widely been underestimated, as a considerable number of patients would need an aspirin provocation test to confirm the diagnosis. N-ERD physiopathology is somehow complex, but basically involves an imbalance in the arachidonic acid metabolite pathway. The syndrome is characterized by the presence of asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and NSAID and aspirin intolerance. Despite maximal and comprehensive medical treatment, the disease tends to be severe, with difficult to treat asthma and highly aggressive and recurrent ethmoidal polyposis. Recently, monoclonal antibodies aimed at reducing type 2 inflammation have demonstrated very promising results on disease control. The goal of this review is to provide the most recent published advances and evidence on physiopathology, diagnostic protocols and therapeutic strategies of N-ERD.

    Keywords: Aspirin exacerbated respiratory disease, AERD, NERD, SAMTER'S triad, Chronic rhinosinusitis, Nasal polyposis

    Received: 11 Jul 2024; Accepted: 07 Nov 2024.

    Copyright: © 2024 Ley Tomas, Xicotencatl Tellez, Garcia Cruz and Jimenez Chobillon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Marcos Alejandro Jimenez Chobillon, IAPA 's clinic, Department of Otorhinolaryngology–Head and Neck Surgery, National Institute of Respiratory Diseases-Mexico (INER), Mexico City, 14080, México, Mexico

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.